Background Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a non-steroidal anti-inflammatory drug used as an adjuvant to sensitize cancer cells to apoptosis. However, in rats suffering from acute rejection, celecoxib reduced apoptosis of myocardial cells. We hypothesize that celecoxib reduces myocardial apoptosis either by inducing apoptosis in peripheral blood lymphocytes (PBLs) or by altering the percentage of CD4 + and CD8 + lymphocytes.
Methods After cardiac transplantation, rats were administered intragastrically with celecoxib (50 mg/kg per day) for 3, 5 or 7 days, at which time the graft was excised and evaluated for organ rejection. In addition, PBLs were isolated from the blood to determine PBLs apoptosis, and the percentage of CD4 + and CD8 + lymphocytes.
Results Celecoxib induced PBLs apoptosis in 3 days, but protected the cells from apoptosis at 5 and 7 days. Also, the percentage of CD4 + lymphocytes decreased only at 3 days, but a reduction in the percentage of CD8 + lymphocytes was not seen until 7 days after the transplant surgery. Celecoxib only decreased acute rejection at 5 days, with no discernible difference in rejection after 3 and 7 days.
Conclusions The results suggested that celecoxib displayed a multiple physiological function in a time-dependent manner. Chin Med J 2009; 122(2) : [188] [189] [190] [191] [192] elecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is the only non-steroidal anti-inflammatory drug so far which is prescribed as an adjuvant treatment for patients with familial adenomatous polyposis. 1 Celecoxib exerts its anti-tumor effect by sensitizing cancer cells to apoptosis through upregulating death receptor 5 (DR5) and the ligand for DR5, 2 upregulating non-steroidal anti-inflammatory drug activated gene (NAG)-1, 3 inhibiting epidermal growth factor receptor, 4 and increasing plasma membrane permeabilization, as detected by increased intracellular Ca 2+ levels and K + efflux from cells, 5 etc. In contrast, celecoxib protects myocardial cells from apoptosis, as well as ameliorating acute rejection, in rats after cardiac transplantation. 6 The mechanism by which celecoxib induces differential apoptotic effects is not fully understood. Graft acute rejection is mediated by cardiomyocyte apoptosis 7 and peripheral blood lymphocytes (PBLs) immune effects including CD4 + T lymphocyte-mediated helpful function and CD8 + T lymphocyte (CTL)-mediated cytotoxicity, etc. 8, 9 All of them are important obstacles for successful transplantation. 10 Celecoxib can reduce T lymphocyte growth, induce apoptosis, 11 regulate CD4 + T cell numbers, 12 either directly or indirectly inhibit CD8 + T-cell activation, which can attenuate cardiomyocyte apoptosis. 7 So we hypothesize that celecoxib may ameliorate rejection and protect myocardial cells from apoptosis which is associated with inducing PBLs apoptosis by altering mitochondrial function 12, 13 or reducing the number of CD4 + /CD8 + lymphocytes. Indeed, the disruption of the mitochondrial transmembrane potential is one of the earliest intracellular events that occurred following induction of apoptosis. 14, 15 In this study, we investigated the ability of celecoxib to induce apoptosis by disrupting the mitochondrial transmembrane potential in PBLs, as well as altering the quantities of CD4 + and CD8 + lymphocytes, and ameliorating acute rejection in rats following heart transplantation.
METHODS

Animals
Forty-two male Wistar rats (200-250 g body weight) and 42 male Sprague-Dawley (SD) rats (300-350 g body weight), purchased from Shanghai Slac Laboratory Animal Co. (SCXK 2003-0003, Shanghai, China), were maintained under a 12-hour light/dark cycle at 22°C with a humidity of (60±10)%. All animals between groups have no statistical significance of differences in physiological parameters. The animals were maintained in a pathogen-free animal facility C and allowed to acclimatize for 3 weeks. The animal experiments were performed in accordance with Administration for Experiment Animal Licence of China.
Drug preparation and treatment
Hearts of Wistar rats were transplanted into the abdominal cavity of SD rats based on a modification of the technique described by Ono and Lindsey. 16 The aorta and pulmonary artery of donor heart were anastomosed to the abdominal aorta and inferior vena of the recipient, respectively. The recipient rats were randomly divided into six groups, with 8 rats per treatment group (T-I, T-II and T-III), and 6 rats per control group (C-IV, C-V and C-VI). Celecoxib (Pfizer, USA) powder was dissolved in 0.9% sodium chloride at a concentration of 20 mg/ml, then administered intragastrically (50 mg/kg per day; T-I from day 0 to day 3, T-II from day 0 to day 5, and T-III from day 0 to day 7 after the operation). The rats in the control groups had the same volume of 0.9% sodium chloride administered intragastrically (C-IV from day 0 to day 3, C-V from day 0 to day 5, and C-VI from day 0 to day 7 after operation).
The viability of donor hearts was evaluated by daily palpation and pathological examination by a blinded observer. Daily palpation was recorded based on scoring from grade I to V: Grade I: complete arrest, regarded as a sign of terminal rejection; grade II: increased consistency and size, with only vibrations of the graft (no beats) when touched; grade III: a tickling sensation felt during deep palpation; grade IV: vigorous beats felt during mild palpation; grade V: observable heart beats directly outside the abdominal wall. 17
Histological examination
The grafts were removed for pathological assessment 3, 5 or 7 days post-transplantation and preserved in 10% formalin. The fixed grafts were sent to the Pathological Research Center of the Harbin Medical University for processing pathological sections by HE staining. All pathological sections were examined with a light microscope. A computer-based imaging collection software application (Motic Images 2000 Version 1.3, China) was used to record objectively the degree of rejection. Data were scored by a blinded observer using International Society for Heart Transplantation Rejection Standard. 18
Isolation of rat PBLs
Briefly, 4 ml of peripheral blood were collected from recipient inferior vena into two anticoagulation tubes, each containing 3.6 mg EDTA (B.D. Franklin Lakes, NJ, USA), diluted 1:1 in phosphate-buffered saline (PBS), then layered on Isolation Liquid 1083 (Tianjin Hao Yang Biological Manufacture Co. Ltd., China) for density gradient centrifugation, respectively. After centrifugation at 530×g for 15 minutes at room temperature, the PBLs in the interface were carefully collected with a pipette and washed twice in PBS. Finally, the PBLs were collected for preparation of cells in next step.
Measurement of mitochondrial transmembrane potential
PBLs apoptosis was detected by measuring the disruption of mitochondrial transmembrane potential using the Mito Capture Apoptosis Detection Kit (BioVision, USA) according to the manufacturer′s instructions. Briefly, 1 µl of MitoCapture was diluted in 1 ml pre-warmed Incubation Buffer for each assay. Cells were suspended in 1 ml of the diluted MitoCapture solution and incubated at 37°C in a 5% CO 2 incubator for 15-20 minutes. The percentage of apoptotic PBLs was measured by flow cytometry (EPICS XL, Beckman-Coulter, USA) using Expo32 MultiComp v1.2 software (Beckman-Coulter). Apoptotic PBLs were detected by fluorescein isothiocyanate (FITC) channel (525 nanometer wavelength) and health PBLs were detected by PI channel (625 nanometer wavelength). The control data were obtained by measuring the percentage of PBLs from health SD rats.
Determination of PBL subpopulation
Mouse anti-rat CD4 + FITC monoclone antibody and CD8 + phycoerythrin (PE) monoclonal antibodies were obtained from Caltag Laboratories Co. (USA). PBLs were harvested from 2 ml peripheral blood as described above. At protection from light, 4°C, the PBLs were stained with CD4 + FITC monoclone antibody and CD8 + PE monoclonal antibodies for 30 minutes seperately, and then washed twice in PBS. The cells were then subjected to flow cytometry and the percentages of CD4 + and CD8 + lymphocytes subpopulations were determined.
Statistical analysis
Statistical significance of differences in graft PBLs apoptosis and CD4 + and CD8 + lymphocytes subpopulations between groups was analyzed using the rank sum test (Newman-Keuls). Both daily graft palpation and histological findings were analyzed using Ridit and Nemenyi analyses. Differences were considered statistically significant when P <0.05.
RESULTS
Analysis of graft histology
To evaluate the protective effects of celecoxib on the cardiac grafts, we performed a histological analysis of the graft tissue at the end of the treatment. Both the celecoxib-treated groups and the placebo-treated groups showed increased rejection of the cardiac graft in a time-dependent manner. This included infiltration of mononuclear cells in the intra-parenchymal and perivascular regions of myocardial tissues, myocardial fibrosis, necrosis and transplant vasculopathy. However, in the celecoxib-treated groups, there was a slight increase in the rejection parameters than was seen in the placebo treated group after 5 days (Figure) . After 3 and 7 days, both groups had similar rejection effects in the sections (Figure) . The grafts in celecoxib administration group in 5 days, displayed both a better viability and a better reduction in acute rejection than placebo group (Tables 1 and 2) . The dead recipient rats before the day of sacrifices in six groups were dissected. It suggested that infection that led to peritonitis be responsible for death. The infective examples were depleted in statistical data in each group. 
Analysis of PBLs subpopulations
CD4 + and CD8 + lymphocytes play an important role in acute rejection. Regulation their number or physiological function lead to acute rejection. Using monoclonal antibodies and flow cytometry, we detected the percentages of CD4 + and CD8 + lymphocytes, and determined the ratio of CD4 + /CD8 + in all six groups. Celecoxib decreased the percentage of CD4 + lymphocytes after 3 days and the percentage of CD8 + lymphocyte after 7 days. The three celecoxib-treated groups had no significant change in the percentage of CD4 + and CD8 + lymphocytes compared to placebo administration groups. However, in celecoxib-treated rats, the ratio of CD4 + /CD8 + increased slowly in a time-dependent manner until 7 days after the operation. But, in placebo-treated rats, the ratio decreased in a time-dependent manner ( Table 3) .
Celecoxib altered PBLs apoptosis in a time-dependent manner
Celecoxib altered (induced or inhibited) PBLs apoptosis through disruption or stabilization the mitochondrial transmembrane potential in a time-dependent manner as determined by flow cytometry. At the earliest time point examined (3 days), celecoxib disrupted the mitochondrial transmembrane potential and induced apoptosis (P <0.05). At later time points (5 and 7 days), celecoxib exposure, compared to 3 days, displayed a decreased tendency depending on time in disruption of the mitochondrial transmembrane potential and in induction of apoptosis when compared to the tendency of control groups (P <0.05). Over time, the percentage of apoptotic cells decreased in the celecoxib-exposed grafts, but increased in control grafts (Table 3) . 
DISCUSSION
In this study, we investigated the ability of celecoxib to modulate the induction of apoptosis in PBLs of rats subjected to heart transplantation. Our data suggested that celecoxib induce apoptosis initially, but represses apoptosis at later time points. The different, even contrary, physiological functions of celecoxib in different circumstances remain controversial. As a selective inhibitor of COX-2, celecoxib is used as a non-steroidal anti-inflammatory drug, and chemoprevention of colorectal cancers in vivo or to induce apoptosis in different cells in vitro by raising the levels of arachidonic acid. Increased arachidonic acid inhibits mitochondrial oxidative phosphorylation, thereby increasing the production of reactive oxygen species, 19 decreases mitochondrial membrane potential, 20 up-regulates the BH3 only protein PUMA, 20 and down-regulates the antiapoptotic Bcl-2 family member in myeloid cell leukemia-1, followed by translocation of Bax to mitochondria and cytochrome C release from mitochondria. 5, 21, 22 Celecoxib also induces p53-independent mitochondria-mediated apoptosis, 5, 23 and decreases Bcl-2 levels. 22 In addition, celecoxib reduces cell growth by arresting the cell cycle at the G0/G1 phase, 22 cleaves poly ADP-ribose polymerase-1 (PARP), 22 inhibits NF-κB activation, 22 etc.
In contrast, other studies have demonstrated that celecoxib provides cellular protection, such as attenuating β-amyloid inducing cellular death, preserving rat pheochromocytoma cells in vitro, 24, 25 and inhibiting apoptosis of cardiac myocytes in rats. 6 Interestingly, the concentration of celecoxib can determine the physiological effect. 26 Celecoxib both induces and reduces NF-κB activation, either promoting or decreasing apoptosis depending on a tissue-dependent effect. 22, 27 A similar effect is seen in myocardial cells. 6, 28 Overall, celecoxib has different, even contrary, physiological functions depending on the circumstances, cell type, time, and dosage. In our study, it is very important that celecoxib changed mitochondrial transmembrane potential in different time point to induce cellular apoptosis or not. It maybe relate to the difference of drug concentration in peripheral blood in different time point. 26 Celecoxib ameliorates cardiac grafts acute rejection during the middle stages (day 5) following transplantation. Some reasons may be responsible for it. First, celecoxib prevents myocardial cell apoptosis at 5 days after transplantation. 6 The mechanism perhaps relates to diminishing T cell activation, decreasing IL-2 levels, and inhibiting the transcription of NF-κB and NF-AT-dependent enhancers. The effects are similar to those of cyclosporin A in the early induction of COX-2 mRNA after T cell activation. 29 Second, celecoxib reduces inflammation by stimulating transforming growth factor-β signaling, 30 and inhibiting many different cytokines and chemokines, such as interferon γ, P-selectin, intercellular adhesion molecule-1, and monocyte chemoattractant peptide-1. 31 It does illustrate the role of celecoxib in decreasing rejection in middle stages of transplantation.
Though celecoxib reduced the percentage of CD8 + lymphocyte at 7 days, it did not prevent rejection of the allograft compared to the control group. Since the percentage of CD4 + lymphocytes did not decrease compared to the control group, decreased levels of CD8 + lymphocytes at 7 days may have lead to an increase in T helper cell 1 compared to control group, known to mediate rejection, which would directly kill the cells, negating the anti-apoptosis effect of celecoxib on PBLs after 7 days. Changing the ratio of CD4 + /CD8 + lymphocytes in vivo leading to a sever inflammatory response maybe is responsible for the rejection. 32 In conclusion, celecoxib plays a multiple role depending on the time after the cardiac transplant in rats. It suggested that celecoxib administration displayed some special physiological function in vivo when immune system was activated.
